Skip to content

Effects of cannabidiol-enriched cannabis extraction product on cognitive functions and inflammatory markers in Parkinson disease.

Effects of cannabidiol-enriched cannabis extraction product on cognitive functions and inflammatory markers in Parkinson disease.

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230204001
Enrollment
60
Registered
2023-02-04
Start date
2023-02-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease Cannabidiol enriched cannabis extraction product, Inflammatory marker, Parkinson disease, Cannabidiol, Cognitive function

Interventions

The CBDEP group received standard Parkinson disease treatment as well as sublingual CBDEP produced by a cannabis factory certified by the World Health Organization Good Manufacturing Practices. CBDEP
s Angel cannabis strain using an ethanol extraction technique. It contained 100 mg of cannabidiol per milliliter and 3.9 mg of tetrahydrocannabinol per milliliter.,The placebo group received standard
s disease treatment as well as sublingual placebo. The placebo contained olive oil, and the placebo and CBDEP containers were identical.
Experimental Drug,Placebo Comparator Drug
CBDEP group,Placebo group

Sponsors

Thai Traditional Medical Knowledge Fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were age more than 40 years, diagnosis of PD using the UK PD Society Brain Bank diagnostic criteria, Hoehn and Yahr Stages 1 to 3, stable dosage of PD medications for at least 3 months, and willingness of patients and caregivers to participate in the study.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had dementia, schizophrenia, or other psychotic disorders; kidney or liver disease; serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >3 times the upper limit of the normal range; or a history of high-risk behavior related to substance abuse, including nicotine, cannabis, and alcohol.

Design outcomes

Primary

MeasureTime frame
Delay Recall 12 weeks Thai Montreal Cognitive Assessment delayed recall

Secondary

MeasureTime frame
Inflammatory markers 12 weeks ( white blood cell counts, erythrocyte sedimentation rate, C- reactive protein, ferritin level),Disease severity 12 weeks UPDRS III,Anxiety and depression 12 weeks HADS,Cognitive function 12 weeks MOCA ,LAB 12 weeks Renal and liver functions,side effect 12 weeks side effect,CBD level 12 weeks Serum CBD

Countries

Thailand

Contacts

Public ContactWitoon Mitarnun

Buriram Hospital

miwitoon@gmail.com66885811134

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026